Drug news
Ozanimod for the treatment of adults with relapsing forms of multiple sclerosis
Celgene Corporation announced that the Company has submitted a New Drug Application to the FDA for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5).
The pivotal efficacy and safety data provided in the application result from the SUNBEAM and RADIANCE Part B phase III, multicenter, randomized, double-blind, double-dummy, active-controlled trials. Earlier this month, the Company also submitted a Marketing Authorization Application to the European Medicines Agency for adults with relapsing-remitting multiple sclerosis.